These data were provided at the 53rd Annual Interacting with of the American Society of Hematology in NORTH PARK, CA. At a median follow-up of 15 a few months and a median of five cycles of therapy, the entire response rate for 35 evaluable patients was 72 percent, with 15 patients achieving a comprehensive response and 11 achieving hematologic improvement read . Three patients acquired progressive disease while on therapy. The median duration of full response finally study assessment was 16 months and median general survival for sufferers achieving a complete response was 27 weeks . Seven comprehensive responders progressed to AML at a median of 20 weeks from achieving complete response. Grade 3/4 non-hematologic adverse events included cardiac , febrile neutropenia , other contamination , pulmonary , vascular access-related thrombosis , CNS hemorrhage or additional .